Table 4 Summary of concomitant SLE medication use (excluding glucocorticoids) received during the 6 months before index, or at index, and during 6 months post-index
Concomitant SLE medications, n (%)a | At or 6 months prior to index Enrolled set (N = 59) | During 6 months post-index Enrolled set (N = 59) |
|---|---|---|
Any of the below | 54 (91.5) | 48 (81.4) |
Antimalarials | 52 (96.3) | 45 (93.8) |
Azathioprine | 12 (22.2) | 9 (18.8) |
Mycophenolate mofetil | 12 (22.2) | 7 (14.6) |
Rituximab | 7 (13.0) | 1 (2.1) |
Methotrexate | 5 (9.3) | 6 (12.5) |
Cyclophosphamide | 1 (1.9) | -b |
NSAIDs | 1 (1.9) | -b |